Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential diagnosis of suspected multiple sclerosis: a consensus approach.
Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Miller DH, et al. Among authors: hutchinson m. Mult Scler. 2008 Nov;14(9):1157-74. doi: 10.1177/1352458508096878. Epub 2008 Sep 19. Mult Scler. 2008. PMID: 18805839 Free PMC article.
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.
Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ. Gold R, et al. Among authors: hutchinson m. Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11. Mult Scler. 2017. PMID: 27207449 Free PMC article. Clinical Trial.
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Polman CH, et al. Among authors: hutchinson m. Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366. Ann Neurol. 2011. PMID: 21387374 Free PMC article.
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Rudick RA, et al. Among authors: hutchinson m. Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212. Mult Scler. 2009. PMID: 19667023
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. Kuhle J, et al. Among authors: hutchinson m. Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362898 Clinical Trial.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Balcer LJ, et al. Among authors: hutchinson m. Neurology. 2007 Apr 17;68(16):1299-304. doi: 10.1212/01.wnl.0000259521.14704.a8. Neurology. 2007. PMID: 17438220 Clinical Trial.
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Miller DH, et al. Among authors: hutchinson m. Neurology. 2007 Apr 24;68(17):1390-401. doi: 10.1212/01.wnl.0000260064.77700.fd. Neurology. 2007. PMID: 17452584 Clinical Trial.
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Rudick RA, et al. Among authors: hutchinson m. Ann Neurol. 2007 Oct;62(4):335-46. doi: 10.1002/ana.21163. Ann Neurol. 2007. PMID: 17696126 Clinical Trial.
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. Hutchinson M, et al. J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. J Neurol. 2009. PMID: 19308305 Free article. Clinical Trial.
1,484 results